Allison H Oakes1, Ritu Sharma2, Madeline Jackson2, Jodi B Segal3. 1. Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD. Electronic address: aoakes2@jhu.edu. 2. Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD. 3. Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD; Johns Hopkins University Center for Health Services and Outcomes Research, Baltimore, MD.
Abstract
BACKGROUND: The overuse of radiologic services, where imaging tests are provided in circumstances where the propensity for harm exceeds the propensity for benefit, comprises a risk to patient safety and a burden on health care systems. Advanced imaging in the staging of low-risk prostate cancer is considered an overused procedure by many professional societies, yet the determinants that drive this phenomenon are not fully appreciated. METHODS: We systematically searched published literature within MEDLINE and Embase from January 1998 to March 2017. We searched for studies conducted in the United States that contain original data and describe determinants associated with the overuse of imaging in low-risk prostate cancer. Paired reviewers independently screened abstracts, assessed quality, and extracted data. We synthesized the identified determinants as patient-level, clinician-level, or system-level factors of overuse. RESULTS: A total of 14 articles were included; the 13 empirical studies defined overuse as being the use of imaging that was discordant with clinical guidelines. Patient- and system-related factors were most commonly described as being associated with overuse; clinician-level determinants were examined infrequently. Older patient age (n = 5), more patient comorbidities (n = 7), and characteristics related to geography (n = 6), higher regional income (n = 6), and less education (n = 5) were the most consistently identified statistically significant determinants of overuse. Meaningful differences were detected between health care settings; large integrated health care systems provided less variable care and had lower rates of overuse. Clinical indicators related to prostate cancer were inconsistently associated with overuse. CONCLUSION: Many patient- and system-related determinants were identified as contributing to the overuse of advanced imaging to stage low-risk prostate cancer. Overuse may be the consequence of systematized clinician behavior and be relatively invariant of patient characteristics. The identified system-level determinants suggest that payment models that are not tied to volume or that reward, enhanced care co-ordination may curb overuse. We propose further examination of physician-level determinants and implore researchers to rank the relative importance of the identified factors and to test their influence through experimental and quasi-experimental methods.
BACKGROUND: The overuse of radiologic services, where imaging tests are provided in circumstances where the propensity for harm exceeds the propensity for benefit, comprises a risk to patient safety and a burden on health care systems. Advanced imaging in the staging of low-risk prostate cancer is considered an overused procedure by many professional societies, yet the determinants that drive this phenomenon are not fully appreciated. METHODS: We systematically searched published literature within MEDLINE and Embase from January 1998 to March 2017. We searched for studies conducted in the United States that contain original data and describe determinants associated with the overuse of imaging in low-risk prostate cancer. Paired reviewers independently screened abstracts, assessed quality, and extracted data. We synthesized the identified determinants as patient-level, clinician-level, or system-level factors of overuse. RESULTS: A total of 14 articles were included; the 13 empirical studies defined overuse as being the use of imaging that was discordant with clinical guidelines. Patient- and system-related factors were most commonly described as being associated with overuse; clinician-level determinants were examined infrequently. Older patient age (n = 5), more patient comorbidities (n = 7), and characteristics related to geography (n = 6), higher regional income (n = 6), and less education (n = 5) were the most consistently identified statistically significant determinants of overuse. Meaningful differences were detected between health care settings; large integrated health care systems provided less variable care and had lower rates of overuse. Clinical indicators related to prostate cancer were inconsistently associated with overuse. CONCLUSION: Many patient- and system-related determinants were identified as contributing to the overuse of advanced imaging to stage low-risk prostate cancer. Overuse may be the consequence of systematized clinician behavior and be relatively invariant of patient characteristics. The identified system-level determinants suggest that payment models that are not tied to volume or that reward, enhanced care co-ordination may curb overuse. We propose further examination of physician-level determinants and implore researchers to rank the relative importance of the identified factors and to test their influence through experimental and quasi-experimental methods.
Authors: Wesley W Choi; Stephen B Williams; Xiangmei Gu; Stuart R Lipsitz; Paul L Nguyen; Jim C Hu Journal: J Urol Date: 2011-03-17 Impact factor: 7.450
Authors: J Michael McWilliams; Jesse B Dalton; Mary Beth Landrum; Austin B Frakt; Steven D Pizer; Nancy L Keating Journal: Ann Intern Med Date: 2014-12-02 Impact factor: 25.391
Authors: Danil V Makarov; Rani A Desai; James B Yu; Richa Sharma; Nitya Abraham; Peter C Albertsen; David F Penson; Cary P Gross Journal: J Urol Date: 2011-11-16 Impact factor: 7.450
Authors: Ramzi G Salloum; Maureen O'Keeffe-Rosetti; Debra P Ritzwoller; Mark C Hornbrook; Jennifer Elston Lafata; Matthew E Nielsen Journal: J Oncol Pract Date: 2017-02-21 Impact factor: 3.840
Authors: Daniel J Morgan; Shannon Brownlee; Aaron L Leppin; Nancy Kressin; Sanket S Dhruva; Les Levin; Bruce E Landon; Mark A Zezza; Harald Schmidt; Vikas Saini; Adam G Elshaug Journal: BMJ Date: 2015-08-25
Authors: Yazmine Lunn; Rudra Patel; Timothy S Sokphat; Laura Bourn; Khalil Fields; Anna Fitzgerald; Vandana Sundaresan; Greeshma Thomas; Michael Korvink; Laura H Gunn Journal: Healthcare (Basel) Date: 2022-01-28
Authors: Danil V Makarov; Shannon Ciprut; Dawn Walter; Matthew Kelly; Heather T Gold; Xiao-Hua Zhou; Scott E Sherman; Ronald Scott Braithwaite; Cary Gross; Steven Zeliadt Journal: JAMA Netw Open Date: 2018-08-03